返回 
加入收藏
恩替卡韦联合介入疗法用于HBV DNA阴性乙肝肝癌的疗效观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 恩替卡韦联合介入疗法用于HBV DNA阴性乙肝肝癌的疗效观察 |
| TITLE： | |
| 摘要： | 目的：观察恩替卡韦联合介入疗法用于乙型肝炎（以下简称“乙肝”）病毒（HBV）DNA阴性乙肝肝癌的临床疗效。方法：选取HBV DNA阴性乙肝肝癌患者100例，按随机数字表法分为观察组和对照组，各50例。对照组患者接受介入治疗，经股动脉入路穿刺，将注射用盐酸吡柔比星+超液化碘油注入载瘤动脉，至载瘤动脉血流停滞，同时进行常规保肝治疗；观察组患者在对照组基础上加服恩替卡韦片1 mg，qd，持续治疗6个月。比较两组患者的临床疗效、HBV DNA定量、Child-Pugh评分和肝功能指标。 结果：观察组患者总缓解率为44.0％，显著高于对照组的26.0％，差异有统计学意义（P＜0.05）。两组患者治疗前的HBV DNA定量、Child-Pugh评分及肝功能指标比较，差异均无统计学意义（P＞0.05）；治疗后，观察组患者的HBV DNA定量、Child-Pugh评分、甲胎蛋白、丙氨酸转氨酶、总胆红素及天冬氨酸转氨酶均明显降低，与对照组比较差异均有统计学意义（P＜0.05）。结论：恩替卡韦联合介入疗法能明显提高HBV DNA阴性乙肝肝癌临床疗效，改善患者肝功能指标。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy of entecavir combined with intervention in the treatment of liver cancer patients with HBV DNA-negative hepatitis B. METHODS： 100 liver cancer patients with HBV DNA-negative hepatitis B were randomly divided into observation group and control group， 50 cases in each group. Control group received intervention， percutaneous puncture of femoral artery， then injected Pirarubicin hydrochloride for injection + lipiodol in parent artery until blood stagnation， and also conventional liver protection therapy was conducted； observation group additionally received 1 mg Entecavir tablet， qd， for continuous 6 months. Clinical efficacy， HBV DNA quantification， Child-Pugh score and liver function indexes in 2 groups were compared. RESULTS： The total effective rate in observation group was 44.0％， which was significantly higher than control group （26.0％）， the difference was statistically significant （P＜0.05）. There were no significant differences in HBV DNA quantification， Child-Pugh score and liver function indexes between 2 groups （P＞0.05）. After treatment， HBV DNA quantification， Child-Pugh score， fetoprotein， alanine aminotransferase， total bilirubin and aspartate aminotransferase significantly decreased in observation group， the differences were statistically significant compared with control group （P＜0.05）. CONCLUSIONS： Entecavir combined with intervention can obviously improve the clinical efficacy and liver function indexes of liver cancer patients with HBV DNA-negative hepatitis B. |
| 期刊： | 2016年第27卷第23期 |
| 作者： | 李刚，于翔，谢坪，蒲红 |
| AUTHORS： | LI Gang，YU Xiang，XIE Ping，PU Hong |
| 关键字： | 恩替卡韦；介入治疗；乙型肝炎；肝癌；肝功能；临床疗效 |
| KEYWORDS： | Entecavir； Intervention； Hepatitis B； Liver cancer； Liver function； Clinical efficacy |
| 阅读数： | 283 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
